PR Newswire
LONDON, Feb. 16, 2026
LONDON, Feb. 16, 2026 /PRNewswire/ — Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the Blood Glucose Monitoring Devices Market is projected to grow from USD 16,202.5 million in 2024 to USD 36.8 billion by 2032 at CAGR 10.8% from 2024 to 2032. Market expansion is supported by rising diabetes prevalence and stronger demand for accurate, easy-to-use monitoring tools.
https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
Rising Prevalence of Diabetes
Diabetes prevalence continues to rise worldwide, creating sustained demand for monitoring solutions. Obesity, sedentary behavior, and unhealthy diets contribute to higher diagnosis rates. Many patients require frequent testing to prevent complications and adjust therapy. Long-term disease management increases repeat demand for supplies and device upgrades. Broader screening and earlier diagnosis also increase the monitored population. These dynamics keep monitoring devices essential across the care continuum.
Technological Advancements in Monitoring Devices
Innovation remains a key driver, led by continuous glucose monitoring and connected devices. CGM systems provide real-time data and reduce dependence on frequent fingerstick testing. Smartphone connectivity improves usability through alerts, trend views, and data sharing. For instance, Abbott’s FreeStyle Libre 2 provides real-time glucose data and optional alarms for high and low glucose. These improvements support better adherence and more informed decision-making. Noninvasive approaches also attract attention by aiming to reduce discomfort and improve user experience.
Government Initiatives and Support for Diabetes Care
Public programs focused on diabetes outcomes are supporting access to monitoring tools. Reimbursement policies can improve adoption of advanced systems in eligible populations. National awareness campaigns also increase diagnosis and encourage routine monitoring. Some health systems promote technology adoption to reduce complications and long-term costs. For instance, Medicare coverage in the United States has expanded access to CGM for many insulin-using beneficiaries. Such support improves affordability and strengthens uptake across clinical and home settings. Policy clarity also encourages manufacturers to expand market presence.
Integration with Mobile Health Applications
Mobile integration is accelerating due to high smartphone usage and demand for connected care. Apps help users track trends, log meals, and share data with clinicians. Digital tools also provide reminders and coaching features that support adherence. Remote data review supports better clinical follow-up and therapy adjustments. For instance, Abbott’s FreeStyle LibreLink app allows users to view sensor readings and trends on a smartphone. This connected approach improves engagement and supports more consistent monitoring behavior. App-enabled ecosystems also strengthen brand retention and upgrade cycles.
Rise of Noninvasive Blood Glucose Monitoring Technologies
Noninvasive approaches are gaining attention due to the goal of painless monitoring. Companies are exploring optical and sensor-based methods to avoid blood sampling. Interest remains strong among users who test frequently and experience discomfort. Product development continues to focus on accuracy, calibration stability, and regulatory validation. For instance, DiaMonTech is developing infrared-based glucose measurement through skin tissue. Wider adoption depends on clinical performance and approvals across major markets. Progress in this area could expand usage among under-monitored populations.
Browse the report and understand how it can benefit your business strategy – https://www.credenceresearch.com/report/blood-glucose-monitoring-devices-market
Challenges:
High Cost of Advanced Monitoring Devices
Advanced systems often carry higher upfront and ongoing costs than traditional meters. CGM sensors and replacements can increase monthly spending for many users. Out-of-pocket costs remain a barrier in markets with limited coverage. This can restrict access for low-income and price-sensitive populations. Cost barriers are more visible in emerging markets with uneven reimbursement. Affordability constraints can slow adoption despite strong clinical value. Price pressure also impacts payer negotiations and product positioning.
Regulatory and Compliance Barriers
Regulatory approval requires extensive testing, documentation, and quality controls. New technologies, including noninvasive devices, often face deeper validation needs. Approval timelines can delay launches and increase development costs. Compliance with evolving rules also adds operational complexity. Regional differences across FDA, EMA, and other regulators increase coordination burden. Smaller firms may face higher barriers to scale across countries. These factors can slow innovation rollouts and limit near-term adoption.
Market Segmentation Analysis
By product type, the market includes self-monitoring devices and continuous blood glucose monitoring systems. Self-monitoring devices include meters, test strips, and lancets used widely for daily checks. These products remain essential due to affordability and broad availability. Continuous monitoring devices include sensors, transmitters, receivers, and related insulin delivery integration. CGM adoption is rising due to demand for real-time data and better glycemic control. The segment is especially important for intensive insulin therapy users. Product innovation continues to improve user comfort and data accuracy.
By end-use, the market includes hospitals, diagnostic centers, and home care. Hospitals and diagnostic centers use monitoring tools for frequent checks and acute care settings. Home care remains the largest segment due to rising preference for self-management. Patients increasingly monitor between clinical visits to guide diet and medication adherence. Home use also supports chronic disease management at scale. These patterns strengthen demand for both devices and recurring consumables. Growth in home diagnostics further supports this end-use trend.
Segmentation
By Product
- Self-monitoring Devices
- Blood Glucose Meter
- Testing Strips
- Lancets
- Continuous Blood Glucose Monitoring Devices
- Sensors
- Transmitter & Receiver
- Insulin Pumps
By End-use
- Hospitals
- Home Care
- Diagnostic Centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis
North America leads the market with roughly 40% share, driven by high diabetes prevalence and advanced healthcare infrastructure. Strong reimbursement frameworks support adoption of CGM and connected solutions. Innovation remains strong due to active R&D and fast product cycles. Demand continues to rise as diagnosis rates increase and populations age. Home monitoring remains a key use case across the region. Clinical adoption also remains high in hospitals and specialist settings.
Europe holds about 30% share, supported by aging demographics and expanding diabetes care programs. Countries such as Germany, the United Kingdom, and France lead demand due to strong healthcare systems. Policy focus on prevention and chronic disease management supports monitoring adoption. Digital health investments also encourage connected monitoring ecosystems. Regulatory standards promote quality, safety, and performance consistency. These factors support steady adoption of advanced monitoring solutions across the region.
Competitive Landscape
The market is moderately concentrated, with several large companies holding significant share. Abbott, Dexcom, Roche, Medtronic, and other major players lead through strong portfolios and broad distribution. These firms invest heavily in product innovation, sensor accuracy, and digital integration. Brand trust and reimbursement access provide important advantages in adoption. Smaller firms and startups compete through specialized noninvasive concepts and novel wearable models. Partnerships and acquisitions remain common to expand technology capabilities. Patient-centric ecosystems and connected services remain key competitive differentiators.
Key Player Analysis
- Abbott
- Ascensia Diabetes Care Holdings AG
- Dexcom, Inc.
- F. Hoffmann-La Roche Ltd
- Glysens Incorporated
- Insulet Corporation
- Medtronic plc
- Novo Nordisk
- Sanofi
- Thermo Fisher Scientific (Patheon)
- Ypsomed Holdings
Recent Industry Developments
- In April 2025, DexCom, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults aged 18 years and older with diabetes.
- In June 2024, Abbott Laboratories received U.S. FDA clearance for two over-the-counter continuous glucose monitoring systems, Lingo and Libre Rio, both developed on its FreeStyle Libre CGM platform.
- In August 2024, Medtronic secured U.S. FDA approval for the Simplera continuous glucose monitor, its first fully disposable, all-in-one CGM device, designed at nearly half the size of earlier Medtronic CGM models.
- In October 2025, OSR Holdings signed a definitive agreement to acquire Woori IO, a developer of noninvasive glucose monitoring technology, through a share exchange transaction.
- In April 2025, Cardinal Health completed the acquisition of Advanced Diabetes Supply Group, strengthening its at-home diabetes care portfolio, including continuous glucose monitoring systems from leading manufacturers.
- In March 2024, DexCom, Inc. announced that the U.S. FDA cleared Stelo by Dexcom as the first glucose biosensor approved for over-the-counter use without a prescription.
- In May 2024, the U.S. FDA cleared the first over-the-counter continuous glucose monitor for marketing in the United States, expanding direct consumer access to CGM technology.
- In June 2024, Abbott Laboratories confirmed U.S. FDA clearance for Lingo and Libre Rio, targeting wellness-focused consumers and adults with type 2 diabetes who do not use insulin, respectively.
Reasons to Purchase this Report:
- Take an in-depth look at the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion).
- Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region.
- Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years.
- Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning.
- Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions.
- Benefit from Porter’s Five Forces analysis and value chain insights to evaluate various market perspectives and competitive dynamics.
- Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years.
Browse the report and understand how it can benefit your business strategy – https://www.credenceresearch.com/report/blood-glucose-monitoring-devices-market
Discover additional reports tailored to your industry needs.
Implantable Continuous Glucose Monitoring Market https://www.credenceresearch.com/report/implantable-continuous-glucose-monitoring-market
Non-Invasive Glucose Monitoring Market https://www.credenceresearch.com/report/non-invasive-glucose-monitoring-market
Continuous Glucose Monitoring Devices Market https://www.credenceresearch.com/report/continuous-glucose-monitoring-devices-market
Glucose Monitoring System Market https://www.credenceresearch.com/report/glucose-monitoring-system-market
Self-Monitoring Blood Glucose Devices Market https://www.credenceresearch.com/report/self-monitoring-blood-glucose-devices-market
Point of Care Glucose Testing Market https://www.credenceresearch.com/report/point-of-care-glucose-testing-market
Patient Monitoring Devices Market https://www.credenceresearch.com/report/patient-monitoring-devices-market
Glucose Biosensors Market https://www.credenceresearch.com/report/glucose-biosensors-market
Network Point of Care Glucose Testing Market https://www.credenceresearch.com/report/network-point-of-care-glucose-testing-market
Revolutionizing Healthcare: The Growth of Vietnam Saliva Glucose Biosensor Market https://www.credenceresearch.com/news/revolutionizing-healthcare-the-growth-of-vietnam-saliva-glucose-biosensor-market
Glucometer Market https://www.credenceresearch.com/report/glucometer-market
Diabetes Diagnostics Market https://www.credenceresearch.com/report/diabetes-diagnostics-market
Veterinary Glucometers Market https://www.credenceresearch.com/report/veterinary-glucometers-market
Follow Us:
https://www.linkedin.com/company/credenceresearch/
https://x.com/CredenceResearc
https://www.facebook.com/CredenceResearch
About Us:
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives.
Contact Us
Credence Research Inc., Tower C-1105, S 25, Akash Tower,Vishal Nahar, Pimple Nilakh,Haveli,Pune – 411027, IndiaEurope–+44 7453 598 606North America – +1 304 308 1216Australia – +61 4192 46279Asia Pacific – +81 5050 50 9250+64 22 017 0275India – +91 6232 49 3207 [email protected] www.credenceresearch.com
Logo: https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/blood-glucose-monitoring-devices-market-to-reach-usd-36-8-billion-by-2032–fueled-by-cgm-adoption-and-home-diagnostics–credence-research-302688856.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…